legitcryptogames2022| Bailitianheng independently developed BL-M07D1: The first subject in the phase III clinical trial was successfully enrolled

News summary

Bailitianheng announced that the first subject in the Phase III clinical trial of its innovative biopharmaceutical BL-M07D1 monotherapy for the treatment of HER2-positive breast cancer has been enrolled. It has a wide range of indications and covers a variety of solid tumors.

Newsletter text

[Bailitianheng has made new progress in the field of biopharmaceuticals] On May 26, Bailitianheng Company announced that its independent research and developmentlegitcryptogames2022The innovative biopharmaceutical BL-M07D1 (HER2-ADC) has successfully developed locally advanced or metastatic HER2-positive breast cancerlegitcryptogames2022The first subject was found. BL-M07D1 is an ADC drug targeting HER2. Its treatment targets include breast cancer, gastric cancer, non-small cell lung cancer, gynecological and urinary tumors and other solid tumors.

Tags:

Prev: bonuspokerstrategycard| Suzhou Shangma Chemical and Anhui Xinwang Chemical: The price of industrial-grade white sugar is 3600 yuan/ton
Next: gamblingbonus| China Telecom and Indonesia sign memorandum of understanding on cybersecurity cooperation: deepening cooperation and expanding areas